
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
This white paper describes the complexity of GI trials in detail and shows how a therapeutic specific data capture solution can overcome their significant, but typical, challenges. Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct.






